<SEC-DOCUMENT>0000947871-23-000446.txt : 20230410
<SEC-HEADER>0000947871-23-000446.hdr.sgml : 20230410
<ACCEPTANCE-DATETIME>20230410215017
ACCESSION NUMBER:		0000947871-23-000446
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230410
DATE AS OF CHANGE:		20230410

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galecto, Inc.
		CENTRAL INDEX KEY:			0001800315
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				371957007
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-39655
		FILM NUMBER:		23812261

	BUSINESS ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		45-70-70-52-10

	MAIL ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galecto Inc.
		DATE OF NAME CHANGE:	20200116

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORBIMED ADVISORS LLC
		CENTRAL INDEX KEY:			0001055951
		IRS NUMBER:				133976876
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 739-6400

	MAIL ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: ORBIMED ADVISORS LLC -->
          <cik>0001055951</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001800315</issuerCik>
      <issuerName>Galecto</issuerName>
      <secFileNumber>001-39655</secFileNumber>
      <issuerAddress>
        <com:street1>75 State Street</com:street1>
        <com:street2>Suite 100</com:street2>
        <com:city>Boston</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02109</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>45-70-70-52-10</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Genesis Master Fund, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Shareholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Themis Trading LLC</name>
        <address>
          <com:street1>10 Town Square</com:street1>
          <com:street2>Suite 100</com:street2>
          <com:city>Chatham</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07928</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>1686</noOfUnitsSold>
      <aggregateMarketValue>3203.40</aggregateMarketValue>
      <noOfUnitsOutstanding>25673474</noOfUnitsOutstanding>
      <approxSaleDate>04/10/2023</approxSaleDate>
      <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>09/25/2020</acquiredDate>
      <natureOfAcquisitionTransaction>Private placement</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>1686</amountOfSecuritiesAcquired>
      <paymentDate>09/25/2020</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>OrbiMed Genesis Master Fund, L.P.</name>
        <address>
          <com:street1>601 Lexington Ave.</com:street1>
          <com:street2>54th Floor</com:street2>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10022</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <saleDate>04/05/2023</saleDate>
      <amountOfSecuritiesSold>4687</amountOfSecuritiesSold>
      <grossProceeds>10217.66</grossProceeds>
    </securitiesSoldInPast3Months>
    <remarks>OrbiMed Genesis GP LLC is the general partner of OrbiMed Genesis Master Fund, L.P. OrbiMed Advisors LLC is the managing member of OrbiMed Genesis GP LLC. Additional sales made on April 6, 2023. OrbiMed Genesis GP LLC sold 487 shares of Common Stock for gross proceeds of $974.</remarks>
    <noticeSignature>
      <noticeDate>04/10/2023</noticeDate>
      <signature>/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Genesis Master Fund, L.P.</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
